Results 81 to 90 of about 2,650 (185)
Aging Cell, Volume 24, Issue 4, April 2025.Metabolomic aging acceleration may help stratify mortality and obesity‐related morbidities risk across different BMI categories. Weight management should address Individuals with overweight or obesity, regardless of metabolomic aging, while delaying metabolomic aging is crucial for all metabolomically older groups, including those with normal weight ...
Xiaomin Zeng +9 more
wiley +1 more source
The initial results of using brolucizumab (Beovu®), an angiogenesis inhibitor, for choroidal neovascularization in patients with age-related macular degeneration [PDF]
Клиническая офтальмология, 2022 N.S. Zhayvoronok1, O.V. Kolenko1–3, L.P. Danilova1,2, E.L. Sorokin1,3 1Khabarovsk Branch of the S. Fedorov Eye Microsurgery Federal State Institution, Khabarovsk, Russian Federation 2Institute of Advanced Training of Healthcare Specialists ...
N.S. Zhayvoronok +3 more
doaj
Intravitreal Bevacizumab in Neovascular Age-Related Macular Degeneration as First Choice: a New Italian Ruling [PDF]
, 2020 Background: Intravitreal vascular endothelial growth factor (VEGF) inhibitors represent the mainstay of neovascular age-related macular degeneration (nAMD) treatment.
Casalino, Giuseppe +2 more
core +2 more sources
Advanced Science, Volume 12, Issue 11, March 20, 2025.This article demonstrates that the peptide bxyPenetratin (bxyWP) non‐covalently binds to the anti‐vascular endothelial growth factor (VEGF) protein aflibercept via hydrophobic interactions, enabling noninvasive delivery of aflibercept to the choroid and retina through conjunctival‐scleral pathway and effective inhibition of choroidal neovascularization
Xingyan Fan +7 more
wiley +1 more source
Brolucizumab: Evaluation of Compassionate Use of a Complex Anti-VEGF Therapy
Clinical Ophthalmology, 2021 Julianna E Murray, Aaron S Gold, Azeema Latiff, Timothy G Murray Private Practice, Miami Ocular Oncology & Retina, Miami, FL, USACorrespondence: Timothy G MurrayMiami Ocular Oncology & Retina, 6705 Red Road Suite 412, Miami, FL, 33143, USAEmail tmurray ...
Murray JE, Gold AS, Latiff A, Murray TG
doaj
Acta Ophthalmologica, Volume 103, Issue 1, Page 99-108, February 2025.Abstract Purpose To analyse the impact on cost if faricimab is used as the first‐line treatment for neovascular age‐related macular degeneration (nAMD) compared to standard treatment with bevacizumab. Methods Retrospective registry study including real‐world data from the Swedish Macula Registry between 2017 and 2022.
Souad Abdalla +3 more
wiley +1 more source
Anti-vascular endothelial growth factor therapies in ophthalmology [PDF]
Background: Retinal diseases, including neovascular age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion, are leading causes of vision loss worldwide.
Karti, Omer +2 more
core +2 more sources
Occlusive retinal vasculitis associated with intravitreal Faricimab injections [PDF]
Purpose: We describe a case of occlusive vasculitis associated with intravitreal Faricimab (Vabysmo) injections. Methods: A retrospective case report.
De Silva, Samantha R. +5 more
core +2 more sources
Ophthalmology and TherapyIntroduction The aim of this study was to evaluate the efficacy and safety of escalating the dosage of intravitreal brolucizumab in patients with refractory neovascular age-related macular degeneration (AMD).
Jinsoo Kim +3 more
doaj +1 more source
Clinical Ophthalmology, 2023 Debdulal Chakraborty,1 Milan Thakkar,2 Ramesh Venkatesh,3 Sangeeta Roy,4 Maulik Bhavsar,5 Helene Karcher6 1Disha Eye Hospital, Kolkata, West Bengal, India; 2Dr.
Chakraborty D +5 more
doaj